Table 1.
Patient characteristics by treatment
| Variable | Unadjusted data |
Adjusted by IPTWa |
||||
|---|---|---|---|---|---|---|
| Nal-iri (n = 35) |
FOLFIRI (n = 40) |
Std. Diff.b |
Nal-iri (n = 35.4) |
FOLFIRI (n = 39.3) |
Std. Diff.b |
|
| Age, median (IQR) | 63 (60–71) | 64 (60–70) | 0.01 | 63 (58–71) | 64 (59–69) | 0.02 |
| Male | 21 (60) | 19 (48) | 0.25 | 18 (50) | 20 (51) | 0.01 |
| BMI | 0.04 | 0.03 | ||||
| > 25 kg/m2 | 20 (57) | 22 (55) | 18 (50) | 20 (51) | ||
| ≤ 25 kg/m2 | 15 (43) | 15 (38) | 15 (44) | 15 (39) | ||
| Insurance | 0.11 | 0.09 | ||||
| Government | 20 (57) | 25 (63) | 20 (46) | 24 (61) | ||
| Private | 15 (43) | 15 (38) | 15 (44) | 15 (39) | ||
| Prior treatment | ||||||
| Surgery | 11 (31) | 12 (30) | 0.03 | 12 (33) | 12 (32) | 0.04 |
| Radiation | 7 (20) | 12 (30) | 0.23 | 9 (24) | 9 (24) | 0.01 |
| Gemcitabine alone | 12 (34) | 16 (40) | 0.12 | 13 (36) | 15 (38) | 0.03 |
| Gemcitabine combo | 33 (94) | 33 (83) | 0.37 | 31 (88) | 35 (88) | 0.01 |
| Fluoropyrimidine | 13 (37) | 17 (43) | 0.11 | 14 (39) | 16 (41) | 0.04 |
| Irinotecan | 10 (29) | 13 (33) | 0.09 | 11 (31) | 13 (33) | 0.03 |
| Oxaliplatin | 10 (29) | 16 (40) | 0.24 | 12 (33) | 14 (35) | 0.04 |
| Other chemo | 4 (11) | 3 (8) | 0.13 | 4 (9) | 4 (10) | 0.04 |
| Number of prior systemic therapies | 0.06 | 0.06 | ||||
| 1 | 14 (40) | 17 (43) | 16 (44) | 17 (42) | ||
| 2 | 14 (40) | 15 (38) | 13 (37) | 14 (36) | ||
| ≥ 3 | 7 (20) | 8 (20) | 7 (19) | 8 (21) | ||
| Metastatic disease | 30 (86) | 33 (83) | 0.09 | 32 (89) | 34 (86) | 0.09 |
| Site of metastases | 0.3 | 0.13 | ||||
| Hepatic only | 11 (31) | 17 (43) | 14 (38) | 16 (40) | ||
| Extrahepatic | 8 (23) | 6 (15) | 6 (17) | 7 (18) | ||
| Both | 11 (31) | 10 (25) | 12 (34) | 11 (29) | ||
| Baseline CA 19–9 | 0.04 | 0.01 | ||||
| ≥ 1500 U/mL | 19 (54) | 21 (53) | 18 (50) | 20 (50) | ||
| < 1500 U/mL | 16 (46) | 19 (48) | 18 (50) | 20 (50) | ||
| Baseline albumin | 0.09 | 0.03 | ||||
| ≥ 3.5 g/dL | 23 (66) | 28 (70) | 25 (71) | 27 (69) | ||
| < 3.5 g/dL | 12 (34) | 21 (30) | 10 (29) | 12 (31) | ||
| Baseline ECOG | 0.32 | 0.04 | ||||
| 0 | 7 (20) | 5 (13) | 5 (15) | 6 (15) | ||
| 1 | 22 (63) | 31 (78) | 26 (73) | 29 (74) | ||
| 2 | 6 (17) | 4 (10) | 4 (12) | 4 (11) | ||
Data are presented as n (%) unless otherwise indicated
IPTW inverse probability of treatment weighting, Std. Diff. standardized difference, IQR interquartile range, BMI body mass index, CA 19–9 cancer antigen 19–9, ECOG Eastern Cooperative Oncology Group performance status score
a
Reported weighted counts are rounded to the nearest integer and percentages are calculated based on the unrounded weighted counts
b
Standardized difference is used to compare balance in measured variables. A standardized difference > 0.2 may indicate imbalance between groups